Latest News
November 18, 2020
Bayer initiates new G4A Digital Health Partnerships Program
November 17, 2020
Not intended for U.S. and UK Media - Late-Breaking Data from subgroup analysis of Phase III FIDELIO-DKD study presented at the American Heart Association (AHA) Scientific Sessions 2020
Finerenone showed consistent benefits on cardiovascular outcomes in patients with chronic kidney disease and type 2 diabetes with or without history of cardiovascular disease
November 13, 2020
Not intended for U.S. and UK Media
Positive CHMP opinion for extension of rivaroxaban marketing authorization to treat venous thromboembolism (VTE) in children
November 12, 2020
Metagenomi closes USD 65 million Series A financing led by Leaps by Bayer and Humboldt Fund
November 09, 2020
Not intended for U.S. and UK Media
Bayer submits marketing authorization applications for finerenone in the U.S. and the EU for patients with chronic kidney disease and type 2 diabetes
Global Health Policy Blog
Current Topics
All